Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prevention and Control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Development and Evaluation of the T.E.A.C.H. Study: A Randomized Control Trial

NCT06926907
View directory record Official record
Conditions
Child Obesity
Interventions
The Teacher Education and Classroom Habits (T.E.A.C.H.) Program
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Jul 22, 2026, 2:05 AM EDT
Terminated Not applicable Interventional

High Dose Vitamin D Plus Multivitamin in the Prevention of Cluster Headache

NCT04570475
View directory record Official record
Conditions
Cluster Headache
Interventions
Vitamin D, multivitamin, Placebo
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Allergic Disease Onset Prevention Study

NCT05003804
View directory record Official record
Conditions
Atopic Dermatitis, Type 1 Hypersensitivity
Interventions
STMC-103H, Placebo
Biological
Lead sponsor
Siolta Therapeutics, Inc.
Industry
Eligibility
0 Days to 14 Days
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 22, 2026, 2:05 AM EDT
Not yet recruiting Phase 3 Interventional

Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure

NCT07220902
View directory record Official record
Conditions
Severe Preeclampsia, Eclampsia Preeclampsia
Interventions
Levetiracetam, magnesium sulfate
Drug
Lead sponsor
Nebraska Methodist Health System
Other
Eligibility
19 Years and older · Female only
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot

NCT01274637
View directory record Official record
Conditions
Venous Thromboembolism, Postpartum
Interventions
Dalteparin Sodium
Drug
Lead sponsor
Ottawa Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Charlottesville, Virginia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Family Safety Net - Aim 3: Randomized Control Trial

NCT05657119
View directory record Official record
Conditions
Suicide, Accidental Injuries, Firearm Injury
Interventions
MI FSN - Lethal Means Reduction, Scripted FSN - Lethal Means Reduction, General Firearm Safety Intervention - General Firearm Safety, General Firearm Comparison - General Firearm Safety
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Kotzebue, Alaska
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 4 Interventional

EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization

NCT00077753
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
enoxaparin sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
4,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

NCT02116530
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
177
States / cities
Anchorage, Alaska • Burbank, California • Dublin, California + 109 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

NCT06069544
View directory record Official record
Conditions
Malaria
Interventions
BNT165e, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
5
States / cities
Tempe, Arizona • Baltimore, Maryland • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Not applicable Interventional Results available

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

NCT02647658
View directory record Official record
Conditions
Low Back Pain
Interventions
Guideline Based Care plus Psychologically Informed Physical Therapy, Guideline Based Care (GBC)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Jul 22, 2026, 2:05 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

NCT05511363
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
KarXT, Placebo
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
55 Years to 90 Years
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
59
States / cities
Homewood, Alabama • Phoenix, Arizona • Encino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional

YSPSL for Prevention of Delayed Graft Function Part B

NCT00298168
View directory record Official record
Conditions
Kidney Diseases
Interventions
YSPSL, placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity

NCT02873819
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity
Interventions
GL-0817, Hiltonol, Sargramostim, cyclophosphamide, Placebo
Drug
Lead sponsor
Gliknik Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

NCT03238781
View directory record Official record
Conditions
Chronic Migraine or Episodic Migraine
Interventions
Placebo, AMG 301
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

NCT01339260
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Netupitant and Palonosetron, Palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
28
States / cities
Anniston, Alabama • Muscle Shoals, Alabama • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death

NCT00993382
View directory record Official record
Conditions
Arrhythmia Prophylaxis, Ventricular Arrhythmia
Interventions
Celivarone, Amiodarone, Matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
37
States / cities
Huntsville, Alabama • Mobile, Alabama • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 29, 2016 · Synced Jul 22, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

NCT06075264
View directory record Official record
Conditions
Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions
Artesunate ointment, Placebo ointment
Drug
Lead sponsor
Frantz Viral Therapeutics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jul 22, 2026, 2:05 AM EDT
Recruiting Phase 3 Interventional

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452
View directory record Official record
Conditions
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
Interventions
VE303, Placebo
Biological
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

NCT03351244
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 409306, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
32
States / cities
Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Not applicable Interventional

The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants

NCT00964093
View directory record Official record
Conditions
Central Line Bloodstream Infections
Interventions
Silver Alginate
Device
Lead sponsor
Baylor Research Institute
Other
Eligibility
1 Day to 3 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Not yet recruiting Not applicable Interventional

Reset: Enhancing Weight Loss in a Digital Intervention

NCT07032571
View directory record Official record
Conditions
Obesity, Overweight, Weight Loss, Health Behavior, Lifestyle Intervention
Interventions
Core Behavioral Weight Loss Intervention, Limit Red Zone Foods, Limit Eating Window, Increase Protein, Increase Fiber Intake
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

NCT00366834
View directory record Official record
Conditions
Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
86
States / cities
Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jul 22, 2026, 2:05 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

NCT04041284
View directory record Official record
Conditions
Migraine, Major Depressive Disorder
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Jul 22, 2026, 2:05 AM EDT